<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600548</url>
  </required_header>
  <id_info>
    <org_study_id>D-18506</org_study_id>
    <secondary_id>410559/2006-7</secondary_id>
    <nct_id>NCT00600548</nct_id>
  </id_info>
  <brief_title>Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)</brief_title>
  <official_title>Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Ciencia e Innovación, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministério da Saúde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitário Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this trial is that the therapeutic activity and safety of oral miltefosine
      in Brazilian patients with cutaneous leishmaniasis is similar or superior to the intravenous
      standard treatment (meglumine antimoniate - Glucantime®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate or complete cicatrization of the ulcer.</measure>
    <time_frame>6 months after treatment.</time_frame>
    <description>Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.
All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inicial cure rate or complete cicatrization of the ulcer.</measure>
    <time_frame>2 months after treatment.</time_frame>
    <description>Bidirectional measurements of ulcers will be taken of the patients' lesions at the initial visit, and at each follow-up visit with standardized caliper. The area involved will be calculated as the product of the two measurements.
All lesions will be categorized as either active or healed (cured) at follow-up visits. Only lesions with complete re-epithelialization, without raised borders, infiltrations or crusts will be considered healed. Evaluation of the lesions will be performed by 2 clinicians who will be unaware of the group assignment of all patients.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Treatment of Cutaneous Leishmaniasis in Brazil.</condition>
  <arm_group>
    <arm_group_label>1.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine.</intervention_name>
    <description>Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.</description>
    <arm_group_label>1.1</arm_group_label>
    <other_name>Impavido.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate.</intervention_name>
    <description>Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.</description>
    <arm_group_label>1.2</arm_group_label>
    <other_name>Glucantime.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine.</intervention_name>
    <description>Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.</description>
    <arm_group_label>2.1</arm_group_label>
    <other_name>Impavido.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate.</intervention_name>
    <description>Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.</description>
    <arm_group_label>2.2</arm_group_label>
    <other_name>Glucantime.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed (untreated) cutaneous leishmaniasis with localized lesions and
             visualization of amastigotes in tissue samples or a positive culture or diagnosed by
             polymerase chain reaction (PCR) methods or by intradermal skin testing (Montenegro
             test).

          -  Number of lesions: 1 to 5 ulcerative lesions.

          -  Lesion´s diameter: 1 to 5 cm.

          -  Disease duration: up to three months.

        Exclusion Criteria:

        Safety concerns:

          -  Thrombocyte count &lt;30 x 109/l

          -  Leukocyte count &lt;1 x 109/l

          -  Hemoglobin &lt;5 g/100 ml

          -  ASAT, ALAT, AP &gt;3 times upper limit of normal range

          -  Bilirubin &gt;2 times upper limit of normal range

          -  Serum creatinine or BUN &gt;1.5 times upper limit of normal range

          -  Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary)

          -  Immunodeficiency or antibody to HIV

          -  Any non-compensated or uncontrolled condition, such as active tuberculosis, malignant
             disease, severe malaria, HIV, or other major infectious diseases

          -  Lactation, pregnancy (to be determined by adequate test) or inadequate contraception
             in females of childbearing potential for treatment period plus 2 months

        Lack of suitability for the trial:

          -  Negative parasitology (aspirate/smear)or negative Montenegro test

          -  Any history of prior anti-leishmania therapy

          -  Any condition which compromises ability to comply with the study procedures

          -  Concomitant serious infection other than cutaneous

        Administrative reasons:

          -  Lack of ability or willingness to give informed consent (patient and/or parent / legal
             representative)

          -  Anticipated non-availability for study visits/procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo RL Machado, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Bahia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundação de Medicina Tropical do Amazonas</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Posto de Saúde de Corte de Pedra</name>
      <address>
        <city>Tancredo Neto</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>April 14, 2010</last_update_submitted>
  <last_update_submitted_qc>April 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Paulo Roberto Lima Machado</name_title>
    <organization>Universidade Federal da Bahia</organization>
  </responsible_party>
  <keyword>Cutaneous leishmaniasis</keyword>
  <keyword>Miltefosine</keyword>
  <keyword>Meglumine antimoniate</keyword>
  <keyword>L. braziliensis, L. guyanensis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

